Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EBIT (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed EBIT for 16 consecutive years, with $40.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT rose 125.28% year-over-year to $40.8 million, compared with a TTM value of $300.6 million through Dec 2025, up 148.02%, and an annual FY2025 reading of $98.3 million, up 116.36% over the prior year.
  • EBIT was $40.8 million for Q4 2025 at Arrowhead Pharmaceuticals, down from $44.1 million in the prior quarter.
  • Across five years, EBIT topped out at $381.2 million in Q1 2025 and bottomed at -$176.1 million in Q2 2024.
  • Average EBIT over 5 years is -$48.5 million, with a median of -$68.9 million recorded in 2021.
  • The sharpest move saw EBIT crashed 362.0% in 2024, then skyrocketed 402.08% in 2025.
  • Year by year, EBIT stood at -$63.3 million in 2021, then soared by 33.46% to -$42.1 million in 2022, then crashed by 224.07% to -$136.5 million in 2023, then decreased by 18.21% to -$161.4 million in 2024, then soared by 125.28% to $40.8 million in 2025.
  • Business Quant data shows EBIT for ARWR at $40.8 million in Q4 2025, $44.1 million in Q3 2025, and -$165.5 million in Q2 2025.